Entinostat is currently being evaluated in Phase I/II clinical trial (NCT03024437) in combination with atezolizumab (anti PD-L1 antibody) and bevacizumab (anti-VEGF) in advanced RCC patients. The gene discussed is VEGFA; the disease is renal cell carcinoma.